A phase 2 trial evaluated the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in patients with urothelial non-muscle invasive bladder cancer.
Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial ...
Urothelial carcinoma is the most common bladder cancer, with stage 1 indicating early-stage disease confined to the bladder lining. Diagnosis involves urinalysis, cystoscopy, TURBT, and imaging to ...
EORTC GUCG 2418 - STARBURST: Strategies for treatment adaptation following re-evaluation of the bladder after using primary neoadjuvant systemic therapies—An EORTC platform trial. This is an ASCO ...
Treatment with UGN-102 in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer demonstrated beneficial responses. Patients with recurrent low-grade intermediate-risk ...
Richard T. Bryan, PhD, Wenyu Liu, PhD, Sarah J. Pirrie, MSc, Rashid Amir, FRCR, Jean Gallagher, Ana I. Hughes, MSc, Kieran P. Jefferson, FRCS, Allen Knight, MBA ...
Using multiparametric MRI (mpMRI) before surgery reduced time to correct treatment by 45 days for patients with muscle invasive bladder cancer. The imaging procedure was successful for over 92% of ...
Treatments for bladder cancer include surgery, chemotherapy, and radiation therapy. Newer treatment options include immunotherapy and targeted therapy. Doctors may administer medications directly into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results